TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
09/12/2025
Back to search
Official data from USPTO
ARICEUM THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
ARICEUM THERAPEUTICS
ST13
US500000079350974Class
5, 42
Filing
79350974
Registration
7318210
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
26
Latest update
09/17/2025
Trademark type
Word
Nice classes
5, 42
Filing date
08/22/2022
Registration date
03/05/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/05/2024
Last transaction
09/17/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
27
Owner location
DE
Examiner
EISNACH, MICHAEL
Law office
L40
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Ariceum Therapeutics GmbH
Representatives
Molly Buck Richard RICHARD LAW GROUP
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceuticals for use in the treatment of cancer; pharmaceutical drugs for use in the treatment of cancer; pharmaceutical preparations for use in the treatment of cancer; injectable pharmaceuticals for use in the treatment of cancer; chemico-pharmaceutical preparations for use in the treatment of cancer; pharmaceutical preparations and substances for use in the treatment of cancer; pharmaceutical preparations for human use for use in the treatment of cancer; synthetic peptides for pharmaceutical purposes for use in the diagnosis and treatment of cancer; pharmaceutical preparations for medical purposes for use in the treatment of cancer; pharmaceutical preparations for the prevention of tumours; pharmaceutical preparations for the treatment of tumours; pharmaceutical preparations for the treatment of cancer; pharmaceutical products for the treatment of cancer; pharmaceutical preparations and substances for use in oncology; radioactive substances for medical purposes; radioactive materials for medical purposes; radioactive elements for medical use
Class 42
Pharmaceutical products development; pharmaceutical product evaluation; testing of pharmaceuticals; research of pharmaceuticals; pharmaceutical research and development; research relating to pharmaceuticals; conducting clinical trials for pharmaceutical products of others; development of pharmaceutical preparations and medicines; research on the subject of pharmaceuticals; research and development for the pharmaceutical industry; research and development in the pharmaceutical and biotechnology fields; conducting clinical trials for others; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development of pharmaceutical preparations for treating malignant tumours
Publications
History of USPTO decisions and trademark events.
26 publications found
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
09/12/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
09/12/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
08/16/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/06/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/05/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
03/05/2024
GPNX
NOTIFICATION PROCESSED BY IB
12/19/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/19/2023
PUBO
PUBLISHED FOR OPPOSITION
12/19/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
11/29/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
11/29/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/29/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/13/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/10/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/09/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/09/2023
RFNT
REFUSAL PROCESSED BY IB
08/07/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
07/20/2023
RFRR
REFUSAL PROCESSED BY MPU
07/20/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/15/2023
CNRT
NON-FINAL ACTION WRITTEN
06/14/2023
DOCK
ASSIGNED TO EXAMINER
06/08/2023
MAFR
APPLICATION FILING RECEIPT MAILED
10/04/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/30/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
09/29/2022
Continuous trademark protection
Get notified about every new filing that threatens ARICEUM THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.